BRNS · ISSUER CIK 1828185
Barinthus Biotherapeutics plc.
Between Aug 1, 2026 and Oct 29, 2026, 8 Barinthus Biotherapeutics plc. insiders reported $0.00 of open-market purchases and $0.00 of sales on SEC Form 4.
↗8 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. No open-market sales in the window.
$0.00Insider buying
$0.00Insider selling
$0.00Net open-market
Sep 9, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 9, 202616:21 | Sep 9, 2026 | BRNS | Director | D · To issuer | — | −48,256 | 0 | -100% | — | ||
| Sep 9, 202616:20 | Sep 9, 2026 | BRNS | Director | D · To issuer | — | −23,000 | 0 | -100% | — | ||
| Sep 9, 202616:20 | Sep 9, 2026 | BRNS | Director | D · To issuer | — | −3,000 | 0 | -100% | — | ||
| Sep 9, 202616:19 | Sep 9, 2026 | BRNS | Director | D · To issuer | — | −10,506 | 0 | -100% | — | ||
| Sep 9, 202616:19 | Sep 9, 2026 | BRNS | Chief Medical Officer | D · To issuer | — | −361,530 | 0 | -100% | — | ||
| Sep 9, 202616:19 | Sep 9, 2026 | BRNS | Chief Medical Officer | A · Grant | — | +361,530 | 361,530 | New | — | ||
| Sep 9, 202616:18 | Sep 9, 2026 | BRNS | Director | D · To issuer | — | −3,000 | 0 | -100% | — | ||
| Sep 9, 202616:18 | Sep 9, 2026 | BRNS | Chief Executive Officer, Director | D · To issuer | — | −1,243,377 | 0 | -100% | — | ||
| Sep 9, 202616:15 | Sep 9, 2026 | BRNS | Director | D · To issuer | — | −1,700 | 0 | -100% | — |